Event

We are experiencing an unprecedented wave of scientific innovation in oncology, leading to the introduction of a plethora of new cancer treatments, particularly for advanced disease which presents with the highest unmet need. However, this innovation only has value if it reaches indicated patients in a timely manner given the rapid progression associated with advanced disease. Actual (time to) patient access to new treatment options can be slow and considerably differ between countries, jurisdictions, and health systems. Reasons for delays in access to new medications can be access-related aspects, affordability issues and/or the actual implementation in guidelines, clinical practice, and clinical decision-making. The impact for patients can be dramatic: exemplary analyses show a loss of more than 30,000 life years between Europe and the US for only two cancer drugs or of up to 1,740 person-years of life and 1,122 QALYs in Canada for NSCLC drugs. There are opportunities and potential solutions to reduce delay in access: aligned and consistent HTA and pricing/reimbursement across countries, effective implementation of Early Access programs, and regulatory collaborations.

This webinar will address these topics in three parts: the first speaker will set the scene by giving an overview of current treatment advancements and the need for rapid access, representing pharmaceutical manufacturers. The second speaker will cover the health economics perspective by giving examples of how to measure the impact of delayed access while the third speaker will cover the academia perspective by discussing potential solutions to reduce delayed patient access to innovative cancer treatment.